Susquehanna International Group, LLP Abb Vie Inc. Call Options Transaction History

Susquehanna International Group, LLP

$560 Billion
Q3 2024

Call Options

29 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	BUY	$163.84 - $199.33 $139 Million - $170 Million	850,600 Added 27.06%	3,994,000 $789 Million
Q2 2024 Aug 15, 2024	BUY	$154.79 - $180.76 $25.8 Million - $30.2 Million	166,900 Added 5.61%	3,143,400 $539 Million
Q1 2024 May 07, 2024	SELL	$159.82 - $182.1 $181 Million - $206 Million	-1,131,600 Reduced 27.55%	2,976,500 $542 Million
Q4 2023 Feb 14, 2024	SELL	$137.6 - $154.97 $36 Million - $40.6 Million	-261,800 Reduced 5.99%	4,108,100 $637 Million
Q3 2023 Nov 14, 2023	BUY	$133.59 - $154.65 $87.5 Million - $101 Million	654,800 Added 17.63%	4,369,900 $651 Million
Q2 2023 Aug 11, 2023	SELL	$132.51 - $164.9 $25.7 Million - $32 Million	-194,100 Reduced 4.97%	3,715,100 $501 Million
Q1 2023 May 16, 2023	SELL	$144.61 - $166.54 $34.3 Million - $39.6 Million	-237,500 Reduced 5.73%	3,909,200 $623 Million
Q4 2022 Feb 14, 2023	BUY	$138.31 - $165.87 $118 Million - $141 Million	852,100 Added 25.86%	4,146,700 $671 Million
Q3 2022 Nov 14, 2022	SELL	$134.21 - $153.93 $199 Million - $228 Million	-1,483,700 Reduced 31.05%	3,294,600 $442 Million
Q2 2022 Aug 15, 2022	BUY	$137.62 - $174.96 $20.8 Million - $26.5 Million	151,500 Added 3.27%	4,778,300 $732 Million
Q1 2022 May 16, 2022	SELL	$131.98 - $163.75 $15.5 Million - $19.2 Million	-117,500 Reduced 2.48%	4,626,800 $750 Million
Q4 2021 Feb 14, 2022	SELL	$107.43 - $135.93 $2.41 Million - $3.04 Million	-22,400 Reduced 0.47%	4,744,300 $642 Million
Q3 2021 Nov 15, 2021	SELL	$106.4 - $120.78 $142 Million - $162 Million	-1,337,900 Reduced 21.92%	4,766,700 $514 Million
Q2 2021 Aug 11, 2021	BUY	$105.21 - $117.21 $232 Million - $258 Million	2,203,700 Added 56.49%	6,104,600 $688 Million
Q1 2021 May 17, 2021	BUY	$102.3 - $112.62 $55.4 Million - $61 Million	541,500 Added 16.12%	3,900,900 $422 Million
Q4 2020 Feb 16, 2021	BUY	$80.49 - $108.67 $38.8 Million - $52.4 Million	482,500 Added 16.77%	3,359,400 $360 Million
Q3 2020 Nov 16, 2020	SELL	$85.91 - $100.83 $153 Million - $179 Million	-1,775,400 Reduced 38.16%	2,876,900 $252 Million
Q2 2020 Aug 14, 2020	BUY	$73.37 - $98.18 $19.4 Million - $26 Million	264,400 Added 6.03%	4,652,300 $457 Million
Q1 2020 May 15, 2020	BUY	$64.5 - $97.79 $32.3 Million - $49 Million	501,000 Added 12.89%	4,387,900 $334 Million
Q4 2019 Feb 14, 2020	SELL	$72.13 - $90.25 $57 Million - $71.4 Million	-790,700 Reduced 16.9%	3,886,900 $344 Million
Q3 2019 Nov 14, 2019	BUY	$62.98 - $75.72 $70.9 Million - $85.3 Million	1,126,000 Added 31.7%	4,677,600 $354 Million
Q2 2019 Aug 14, 2019	BUY	$65.7 - $83.98 $111 Million - $142 Million	1,685,600 Added 90.33%	3,551,600 $258 Million
Q1 2019 May 15, 2019	SELL	$77.14 - $90.79 $186 Million - $219 Million	-2,414,700 Reduced 56.41%	1,866,000 $150 Million
Q4 2018 Feb 14, 2019	BUY	$77.85 - $96.01 $109 Million - $134 Million	1,397,700 Added 48.48%	4,280,700 $395 Million
Q3 2018 Nov 14, 2018	BUY	$88.91 - $98.84 $2.9 Million - $3.22 Million	32,600 Added 1.14%	2,883,000 $273 Million
Q2 2018 Aug 14, 2018	BUY	$89.78 - $106.23 $16.7 Million - $19.7 Million	185,600 Added 6.96%	2,850,400 $264 Million
Q1 2018 May 15, 2018	SELL	$92.01 - $123.21 $34.4 Million - $46 Million	-373,600 Reduced 12.3%	2,664,800 $252 Million
Q4 2017 Feb 14, 2018	SELL	$89.56 - $98.21 $21.2 Million - $23.2 Million	-236,700 Reduced 7.23%	3,038,400 $294 Million
Q3 2017 Nov 14, 2017	BUY	$69.85 - $89.22 $229 Million - $292 Million	3,275,100	3,275,100 $291 Million

Others Institutions Holding ABBV

# of Institutions

3,853

Shares Held

1.25B

Call Options Held

16.8M

Put Options Held

12.2M

View Full List

About AbbVie Inc.

Ticker ABBV
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,768,099,968
Market Cap $318B
Description
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...

More about ABBV

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

News

Stay updated on Susquehanna International Group, LLP with notifications on news.

Account